GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
Moderna and Merck have been partners in the development of messenger RNA cancer vaccines since 2016. Merck is deepening the alliance by exercising an option that enables it to share equally in further work on a partnered cancer vaccine for melanoma.
Notwithstanding significant progress made in the past decade in the fight against cancer, this disease remains the world's second-largest cause of death, behind cardiovascular disease. Now, mRNA cancer vaccines could offer some hope.
Vaccines developed by Aivita Biomedical use a patient's own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Ugur Sahin presented a sweeping vision of the company's goal to become a next-generation immunotherapy company leveraging the messenger RNA platform technology that has won it acclaim and financial returns during the Covid-19 pandemic.
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal's lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
PsiOxus Therapeutics has signed a second agreement with Bristol-Myers Squibb (BMS), this time for worldwide rights to its 'armed' oncolytic virus NG-348, currently in the preclinical research phase.
BeneVir's cancer vaccines are engineered to incite an immune response, as well as hide from the immune system - so as to have a prolonged anti-cancer effect.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Bay Area cancer vaccine maker Bullet Biotechnology is developing a therapy for B cell lymphomas, hacking a patient’s own immune system to treat these cancers. It takes the typical vaccine approach – targeting a marker exclusive to B cells that elicits a cellular immune response – from both T and B cells. Bullet uses directed conjugation to attach a […]